Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | ADK | P55263 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | ABL2 | P42684 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30940886 | 1.00 | SRC (0.37) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL25049027 | 1.00 | SRC (0.37) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL31617972 | 0.95 | SRC (0.39) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL30941051 | 0.91 | SRC (0.45) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL25047606 | 0.91 | SRC (0.45) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL25048212 | 0.90 | CNR1 (0.32) | HPGDS | |
| SCHEMBL31618059 | 0.90 | CNR1 (0.32) | HPGDS | |
| SCHEMBL30940926 | 0.90 | CNR1 (0.32) | HPGDS | |
| SCHEMBL25046692 | 0.89 | SRC (0.39) | SRCEGFRADKABL1ABL2 | |
| SCHEMBL30941212 | 0.89 | SRC (0.39) | SRCEGFRADKABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | SRC 968/4885EGFR 1687/4885ADK 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.